(Reuters) -British medical products maker Convatec on Thursday forecast double-digit percentage growth in adjusted earnings per share for 2026, banking on new launches and continued demand for its wound care offerings in major markets.
The company, which primarily makes products for chronic condition care, expects growth to be driven by a 5% to 7% rise in organic sales. It confirmed it was on track to deliver its targets for 2025.
“New product launches delivered strong sales growth, offsetting market headwinds and demonstrating the resilience of our business,” CEO Jonny Mason said in a statement.
Shares of the company were up 6.3% at 0844 GMT and were among the top gainers on the blue-chip FTSE 100 index.
Healthcare firms globally are facing U.S. tariff and pricing pressures as President Donald Trump pushes for investments on American soil. His administration has also opened a probe into imports of medical devices.
Organic revenue growth in its advanced wound care unit, which accounted for 32% of Convatec’s total revenue in 2024, was in the mid-single digit percentage range for the ten months ended October 31, driven by North America and emerging markets, the company said.
The outlook and reported results, however, excluded the company’s InnovaMatrix wound care product, as it awaits a decision on reimbursement coverage for the offering under the U.S. government’s Medicare reimbursement policy, which was overhauled earlier this year.
(Reporting by Unnamalai L and Pushkala Aripaka in Bengaluru; Editing by Mrigank Dhaniwala and Eileen Soreng)
